You are here: Welcome to the MPKB » Welcome to the MPKB » Publications & presentations » Applications to the FDA for orphan drug status for Marshall Protocol medications
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
home:publications:applications_orphan_status [04.24.2011] – paulalberthome:publications:applications_orphan_status [07.04.2022] (current) – external edit 127.0.0.1
Line 8: Line 8:
  
  
-  * submitted by ARF (September 2005) - [[http://autoimmunityresearch.org/orphan-app-mino.pdf|Application for Orphan Drug Status]] for minocycline in sarcoidosis +  * submitted by ARF (September 2005) - [[https://autoimmunityresearch.org/orphan-app-mino.pdf|Application for Orphan Drug Status]] for minocycline in sarcoidosis 
-  * FDA approval (March 2006) - [[http://www.fda.gov/orphan/designat/alldes.rtf|minocycline]] as an orphan drug for sarcoidosis+  * FDA approval (March 2006) - [[https://www.fda.gov/orphan/designat/alldes.rtf|minocycline]] as an orphan drug for sarcoidosis
  
 ===== Clindamycin ===== ===== Clindamycin =====
  
  
-  * submitted by ARF (September 2005) - [[http://autoimmunityresearch.org/orphan-clindamycin-25jul06.pdf|Application for Orphan Drug Status]] for clindamycin in treatment of sarcoidosis and Post-Treatment Lyme Disease Syndrome +  * submitted by ARF (September 2005) - [[https://autoimmunityresearch.org/orphan-clindamycin-25jul06.pdf|Application for Orphan Drug Status]] for clindamycin in treatment of sarcoidosis and Post-Treatment Lyme Disease Syndrome 
-  * FDA approval (August 2006) - [[http://www.fda.gov/orphan/designat/alldes.rtf|clindamycin]] as an orphan drug for sarcoidosis+  * FDA approval (August 2006) - [[https://www.fda.gov/orphan/designat/alldes.rtf|clindamycin]] as an orphan drug for sarcoidosis
  
 <html> <html>
Line 22: Line 22:
 ===== Olmesartan ===== ===== Olmesartan =====
  
-  * submitted by ARF (July 2006) - [[http://autoimmunityresearch.org/orphan-app-benicar.pdf|Application for Orphan Drug Status]] for olmesartan in treatment of Post-Treatment Lyme Disease Syndrome+  * submitted by ARF (July 2006) - [[https://autoimmunityresearch.org/orphan-app-benicar.pdf|Application for Orphan Drug Status]] for olmesartan in treatment of Post-Treatment Lyme Disease Syndrome
   * //application pending//   * //application pending//
  
home/publications/applications_orphan_status.1303670464.txt.gz · Last modified: 04.24.2011 by paulalbert
© 2015, Autoimmunity Research Foundation. All Rights Reserved.